Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1657905rdf:typepubmed:Citationlld:pubmed
pubmed-article:1657905lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0042149lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0016030lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0205064lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0021764lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0001443lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0145988lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0623362lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:1657905lifeskim:mentionsumls-concept:C0439596lld:lifeskim
pubmed-article:1657905pubmed:issue30lld:pubmed
pubmed-article:1657905pubmed:dateCreated1991-12-2lld:pubmed
pubmed-article:1657905pubmed:abstractTextInterleukin 1 (IL-1) mediates many cellular functions, but the signal transduction mechanisms of its actions are not clearly understood. Here, we have examined the exact participation of cAMP in the IL-1-induced production of the precursors of matrix metalloproteinase (MMPs) and their specific inhibitor, tissue inhibitor of metalloproteinases (TIMP) in human uterine cervical fibroblasts. IL-1 significantly augmented the production of proMMP-1 (vertebrate procollagenase), proMMP-3 (prostromelysin), and TIMP without detectable changes in the intracellular level of cAMP. Dibutyryl cAMP (Bt2cAMP) and the cAMP elevating agent (forskolin) did not replace IL-1 as MMP inducers. On the contrary, the IL-1-mediated induction of proMMP-1 and proMMP-3 was significantly suppressed by treatment of the cells with Bt2cAMP, forskolin, or theophylline. The suppressive effect of Bt2cAMP on the IL-1-induced production of proMMP-1 and -3 was not due to the inhibition of zymogen secretion, but resulted from the decrease in the steady-state levels of proMMP-1 and proMMP-3 mRNAs. In contrast, Bt2cAMP slightly enhanced the IL-1-induced production of TIMP. The synthesis of proMMP-2 (72-kDa progelatinase/type IV procollagenase) was not altered by IL-1 and/or Bt2cAMP. These results suggest, first, that induction of proMMP-1 and -3 synthesis may share similar transduction pathways but they are distinct from those for proMMP-2 and TIMP synthesis and, second, that cAMP does not function as a second messenger in the MMPs' induction upon IL-1 stimulation in human uterine cervical fibroblasts. Thus, it is further suggested that the system that increases the intracellular cAMP level may be involved in negative regulation of proMMP-1 and -3 production.lld:pubmed
pubmed-article:1657905pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:languageenglld:pubmed
pubmed-article:1657905pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:citationSubsetIMlld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1657905pubmed:statusMEDLINElld:pubmed
pubmed-article:1657905pubmed:monthOctlld:pubmed
pubmed-article:1657905pubmed:issn0021-9258lld:pubmed
pubmed-article:1657905pubmed:authorpubmed-author:TakahashiSSlld:pubmed
pubmed-article:1657905pubmed:authorpubmed-author:ItoAAlld:pubmed
pubmed-article:1657905pubmed:authorpubmed-author:MoriYYlld:pubmed
pubmed-article:1657905pubmed:authorpubmed-author:NagaseHHlld:pubmed
pubmed-article:1657905pubmed:authorpubmed-author:NaginoMMlld:pubmed
pubmed-article:1657905pubmed:authorpubmed-author:XieBBlld:pubmed
pubmed-article:1657905pubmed:issnTypePrintlld:pubmed
pubmed-article:1657905pubmed:day25lld:pubmed
pubmed-article:1657905pubmed:volume266lld:pubmed
pubmed-article:1657905pubmed:ownerNLMlld:pubmed
pubmed-article:1657905pubmed:authorsCompleteYlld:pubmed
pubmed-article:1657905pubmed:pagination19894-9lld:pubmed
pubmed-article:1657905pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:meshHeadingpubmed-meshheading:1657905-...lld:pubmed
pubmed-article:1657905pubmed:year1991lld:pubmed
pubmed-article:1657905pubmed:articleTitleCyclic adenosine 3',5'-monophosphate suppresses interleukin 1-induced synthesis of matrix metalloproteinases but not of tissue inhibitor of metalloproteinases in human uterine cervical fibroblasts.lld:pubmed
pubmed-article:1657905pubmed:affiliationDepartment of Biochemistry, Tokyo College of Pharmacy, Japan.lld:pubmed
pubmed-article:1657905pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1657905pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1657905lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1657905lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1657905lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1657905lld:pubmed